What question did this study set out to answer?

The study aims to analyze treatment patterns and outcomes for patients with AL amyloidosis using real-world data.

November 8, 2025BiomedicinesOpen Access

Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns

View Full Paper

Ask AI

Bookmark

Authors

MMMarko Mitrovic ASAleksandra Sretenovic NKNatalija KecmanHospital Costa del Sol

Discussion

Member takes

Implication

Analysis demonstrates improved hematologic response rates in AL amyloidosis patients treated with Melphalan and stem cell transplantation, highlighting treatment efficacy.

Key Points

The study aims to analyze treatment patterns and outcomes for patients with AL amyloidosis using real-world data.
Analyzed real-world data of 60 patients diagnosed with AL amyloidosis
Evaluated treatment regimens including Bortezomib and alkylating agents
Examined response rates and prognostic factors for clinical outcomes
70% overall response rate achieved in patients
Hematologic response rates significantly better with Melphalan and autologous stem cell transplantation
No difference in progression-free survival between treatment groups, but durable overall survival observed in patients treated with CyBorD + HDT + ASCT

Cite This Study

Mitrovic et al. (2025) studied this question.

synapsesocial.com/papers/69253a39c0ce034ddc357c82 https://doi.org/10.3390/biomedicines13112734

View Full Paper

Ask AI

Bookmark

Implication

Analysis demonstrates improved hematologic response rates in AL amyloidosis patients treated with Melphalan and stem cell transplantation, highlighting treatment efficacy.

Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider